SEC Company Response from AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — May 19, 2017
AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: May 19, 2017 · CIK: 0000946644 · Accession: 0001493152-17-005633
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-27072, 333-217671
Letter
Division of Corporation Finance Securities and Exchange Commission Re: Hemispherx Biopharma, Inc. Registration Statement on Form S-1 Filed May 4, 2017 File No. 333-217671
Dear Ms. Hayes:
On behalf of Hemispherx Biopharma, Inc. (the “Company”), I hereby file Amendment No. 1 (the “Amendment”) to the above referenced registration statement (the “Registration Statement”) and respond to the comments contained in your May 15, 2017 comment letter. Please note that the primary reason for the Amendment is to incorporate by reference filings made after the Registration Statement was filed.
Comment No. 1. We note that you have a pending request for confidential treatment. Please be advised that we will not be in a position to declare your registration statement effective until we resolve any issues concerning the confidential treatment request.
Response: The Commission granted confidential treatment to the Company’s request for confidential treatment (File No. 000-27072 - CF# 34626) on May 16, 2017.
Please note that the Company has filed an acceleration request simultaneously herewith.
Very truly yours,
/s/ Richard
Feiner
Show Raw Text
CORRESP
1
filename1.htm
SILVERMAN
SHIN & BYRNE PLLC
Wall
Street Plaza
22nd
Floor
88
Pine Street
NEW
YORK, NY 10005
212.779.8600
Facsimile:
212.779.8858
__________
New
Jersey
19
Engle Street
Tenafly,
NJ 07670
(201)
567-4969
May
19, 2017
Suzanne
Hayes
Assistant
Director
Division
of Corporation Finance
Securities
and Exchange Commission
100
F Street, NE
Washington,
DC 20549
Re:
Hemispherx Biopharma, Inc.
Registration Statement on Form S-1
Filed May 4, 2017
File No.
333-217671
Dear
Ms. Hayes:
On
behalf of Hemispherx Biopharma, Inc. (the “Company”), I hereby file Amendment No. 1 (the “Amendment”) to
the above referenced registration statement (the “Registration Statement”) and respond to the comments contained in
your May 15, 2017 comment letter. Please note that the primary reason for the Amendment is to incorporate by reference filings
made after the Registration Statement was filed.
Comment
No. 1. We note that you have a pending request for confidential treatment. Please be advised that we will not be in a position
to declare your registration statement effective until we resolve any issues concerning the confidential treatment request.
Response:
The Commission granted confidential treatment to the Company’s request for confidential treatment (File No. 000-27072
- CF# 34626) on May 16, 2017.
Please
note that the Company has filed an acceleration request simultaneously herewith.
Very truly yours,
/s/ Richard
Feiner
Richard Feiner
cc:
Adam Pascale